References

Advances in oligonucleotide drug delivery

10.1038/s41573-020-0075-7 · 2020 · External reference

RNA-targeted therapeutics

10.1016/j.cmet.2018.03.004 · 2018 · External reference

Therapies for rare diseases: therapeutic modalities, progress and challenges ahead

10.1038/s41573-019-0049-9 · 2020 · External reference

Patient-customized oligonucleotide therapy for a rare genetic disease

10.1056/nejmoa1813279 · 2019 · External reference

Unresolved reference

2021 · External reference

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

10.1038/35888 · 1998 · External reference

The current state and future directions of RNAi-based therapeutics

10.1038/s41573-019-0017-4 · 2019 · External reference

Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis

10.1056/nejmoa1716153 · 2018 · External reference

The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs

10.1038/s41565-019-0591-y · 2019 · External reference

Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing

10.1021/ja505986a · 2014 · External reference

Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates

10.1016/j.ymthe.2017.12.021 · 2018 · External reference

Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications

10.1016/j.jconrel.2015.02.022 · 2015 · External reference

The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer

10.1038/gt.2008.60 · 2008 · External reference

Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates

10.1093/nar/gkaa670 · 2020 · External reference

Unresolved reference

External reference

Unresolved reference

2025 · External reference

The approval of Redemplo for familial chylomicronemia syndrome and the many Flavors of GalNAc-oligonucleotides

10.1177/21593337261435980 · 2026 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2026 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2024 · External reference

Unresolved reference

2025 · External reference

The asialoglycoprotein receptor: relationships between structure, function, and expression

10.1152/physrev.1995.75.3.591 · 1995 · External reference

GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics

10.1089/nat.2018.0736 · 2018 · External reference

Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics

10.1016/j.omtn.2016.12.003 · 2017 · External reference

Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug

10.1016/j.ymthe.2020.06.015 · 2020 · External reference

A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system

10.1038/s41587-019-0205-0 · 2019 · External reference

Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates

10.1038/s41587-022-01334-x · 2022 · External reference

Multiple-dose results from an ongoing phase 1 study of Mivelsiran, an investigational RNA interference therapeutic targeting amyloid-Beta precursor protein for Alzheimer’s disease

10.1002/alz70859_097989 · 2025 · External reference

Unresolved reference

2024 · External reference

Divalent siRNA for prion disease

10.1093/nar/gkag287 · 2026 · External reference

Unresolved reference

2024 · External reference

Unresolved reference

External reference

Unresolved reference

2026 · External reference

Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles

10.1016/j.jconrel.2016.06.036 · 2016 · External reference

An antibody-oligonucleotide conjugate for myotonic dystrophy type 1

10.1056/nejmoa2407326 · 2026 · External reference

FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models

10.1038/s43856-025-00733-w · 2025 · External reference

Targeted tissue delivery of RNA therapeutics using antibody-oligonucleotide conjugates (AOCs)

10.1093/nar/gkad415 · 2023 · External reference

Local CpG-Stat3 siRNA treatment improves antitumor effects of immune checkpoint inhibitors

10.1016/j.omtn.2024.102357 · 2024 · External reference

Unresolved reference

2021 · External reference

Unresolved reference

2026 · External reference

Unresolved reference

2024 · External reference

Structural basis for 5′-nucleotide base-specific recognition of guide RNA by human AGO2

10.1038/nature09039 · 2010 · External reference

In vivo activity of nuclease-resistant siRNAs

10.1261/rna.5239604 · 2004 · External reference

Characterization of fully 2′-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity

10.1093/nar/23.11.2019 · 1995 · External reference

Fully 2’-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA

10.1021/jm049167j · 2005 · External reference

Phosphorothioates, essential components of therapeutic oligonucleotides

10.1089/nat.2014.0506 · 2014 · External reference

5′-(E)-Vinylphosphonate: a stable phosphate mimic can improve the RNAi activity of siRNA-GalNAc conjugates

10.1002/cbic.201600130 · 2016 · External reference

5΄-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo

10.1093/nar/gkx507 · 2017 · External reference

Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity

10.1038/s41467-018-02989-4 · 2018 · External reference

From bench to bedside: improving the clinical safety of GalNAc-siRNA conjugates using seed-pairing destabilization

10.1093/nar/gkac539 · 2022 · External reference

Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo

10.1002/cbic.201500023 · 2015 · External reference

Structural optimization of siRNA conjugates for albumin binding achieves effective MCL1-directed cancer therapy

10.1038/s41467-024-45609-0 · 2024 · External reference

siRNA conjugate with high albumin affinity and degradation resistance for delivery and treatment of arthritis in mice and guinea pigs

10.1038/s41551-025-01376-x · 2025 · External reference

Peptide-oligonucleotide conjugation: chemistry and therapeutic applications

10.3390/cimb46100655 · 2024 · External reference

Unresolved reference

External reference

Lipid conjugates enhance endosomal release of antisense oligonucleotides into cells

10.1089/nat.2019.0794 · 2019 · External reference

Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape

10.1038/nbt.2612 · 2013 · External reference

Unresolved reference

2018 · External reference

Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging

10.1093/nar/gkj439 · 2006 · External reference

Phase 3 trial of RNAi therapeutic Givosiran for acute intermittent porphyria

10.1056/nejmoa1913147 · 2020 · External reference

Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1

10.1056/nejmoa2021712 · 2021 · External reference

Two phase 3 trials of Inclisiran in patients with elevated LDL cholesterol

10.1056/nejmoa1912387 · 2020 · External reference

Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy

10.1056/nejmoa2409134 · 2025 · External reference

Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial

10.1016/s2352-3026(23)00037-6 · 2023 · External reference

Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial

10.1016/s0140-6736(23)00284-2 · 2023 · External reference

Plozasiran for managing persistent chylomicronemia and pancreatitis risk

10.1056/nejmoa2409368 · 2025 · External reference

PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2

10.1016/j.kint.2022.07.025 · 2023 · External reference

Unresolved reference

2026 · External reference

Unresolved reference

External reference

Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier

10.1126/scitranslmed.adi2245 · 2024 · External reference

Intravenous administration of blood-brain barrier-crossing conjugates facilitate biomacromolecule transport into central nervous system

10.1038/s41587-024-02487-7 · 2025 · External reference

Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants

10.1084/jem.20131660 · 2014 · External reference

The effects of dose, valency, and affinity on TfR-mediated brain delivery in vivo

10.1186/s12987-025-00643-y · 2025 · External reference

Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier

10.1126/scitranslmed.3005338 · 2013 · External reference

Unresolved reference

External reference

Unresolved reference

2024 · External reference

Unresolved reference

External reference

Development of a DUX4-targeting antibody oligonucleotide conjugate as a therapy for FSHD

10.1093/nar/gkag301 · 2026 · External reference

Unresolved reference

External reference

Unresolved reference

2026 · External reference

Unresolved reference

2025 · External reference

Design of bifunctional RNA-binding compounds that can modulate siRNA hydrophobicity for deep penetration and gene silencing in the retina

10.1016/j.omtn.2025.102751 · 2025 · External reference

Unresolved reference

External reference

RNA-based therapies in inherited retinal diseases

2022 · External reference

Pulmonary siRNA delivery for lung disease: review of recent progress and challenges

10.1016/j.jconrel.2020.11.005 · 2021 · External reference

Dry powder inhalation of siRNA therapeutics: emerging strategies for pulmonary gene silencing

10.1016/j.xphs.2025.104076 · 2026 · External reference

Unresolved reference

2022 · External reference

A first-in-human study of ARO-RAGE, a novel inhaled RNA-interference therapy for asthma

2024 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2020 · External reference

Unresolved reference

2021 · External reference

Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease

10.1016/j.kint.2015.11.007 · 2016 · External reference

Efficient and selective kidney targeting by chemically modified carbohydrate conjugates

10.1016/j.ymthe.2024.10.020 · 2024 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2026 · External reference

A lung-targeted RNAi therapeutics delivery platform compatible with subcutaneous (s.c.) administration mediates pulmonary RAGE silencing in rodents and nonhuman primates

2023 · External reference

Fazirsiran for adults with alpha-1 antitrypsin deficiency liver disease: a phase 2 placebo controlled trial (SEQUOIA)

10.1053/j.gastro.2024.06.028 · 2024 · External reference

Fazirsiran for liver disease associated with alpha(1)-antitrypsin deficiency

10.1056/nejmoa2205416 · 2022 · External reference

Unresolved reference

2023 · External reference

Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington’s disease models

10.1038/s41467-022-33061-x · 2022 · External reference

Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS

10.1093/nar/gkt725 · 2013 · External reference

Huntington’s disease clinical trials update: March 2025

10.1177/18796397251337000 · 2025 · External reference

Tominersen in adults with manifest Huntington’s disease

10.1056/nejmc2300400 · 2023 · External reference

Trial of antisense oligonucleotide tofersen for SOD1 ALS

10.1056/nejmoa2204705 · 2022 · External reference

Unresolved reference

2024 · External reference

Unresolved reference

External reference

RNA interference with zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial

10.1001/jama.2024.0728 · 2024 · External reference

Add-on treatment with zilebesiran for inadequately controlled hypertension: the KARDIA-2 randomized clinical trial

10.1001/jama.2025.6681 · 2025 · External reference

Unresolved reference

External reference

Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease

10.1056/nejmoa2211023 · 2022 · External reference

Unresolved reference

2026 · External reference

Unresolved reference

1999 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

2023 · External reference

Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown

10.1038/nbt.3298 · 2015 · External reference

Delivery of RNA therapeutics: the great endosomal escape!

10.1089/nat.2022.0004 · 2022 · External reference

Imaging small molecule-induced endosomal escape of siRNA

10.1038/s41467-020-15300-1 · 2020 · External reference

Engineered ionizable lipid siRNA conjugates enhance endosomal escape but induce toxicity in vivo

10.1016/j.jconrel.2022.07.041 · 2022 · External reference

Unresolved reference

2023 · External reference

Eplontersen for treating hereditary transthyretin-related amyloidosis

2024 · External reference

Unresolved reference

2021 · External reference

Unresolved reference

2025 · External reference